IRON CHELATION THERAPY IMPROVES HAEMATOLOGICAL RESPONSE IN HIGH-RISK MYELODYSPLASTIC PATIENTS TREATED WITH AZACITIDINE

被引：0
|
作者：
Villa, M. R. [1 ]
Gagliardi, A. [1 ]
Della Cioppa, P. [1 ]
Esposito, M. [1 ]
Lucania, A. [1 ]
Izzo, G. Nitrato [1 ]
Improta, S. [1 ]
Mastrullo, L. [1 ]
机构：
[1] ASL Napoli 1 Ctr, UOC Ematol PO San Gennaro, Naples, Italy
来源：
HAEMATOLOGICA | 2016年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P111
引用
收藏
页码：S120 / S121
页数：2
相关论文
共 50 条
  • [21] Iron Chelation with Deferasirox (Exjade®) Improves Iron Burden in Patients with Myelodysplastic Syndromes (MDS)
    List, Alan F.
    Baer, Maria R.
    Steensma, David
    Raza, Azra
    Esposito, Jason
    Virkus, Jodi
    Paley, Carole
    Feigert, John
    Besa, Emmanuel C.
    BLOOD, 2008, 112 (11) : 236 - 236
  • [22] Patient outcome measures during prolonged survival in patients (Pts) with high-risk myelodysplastic syndromes (MDS) treated with azacitidine (AZA)
    Santini, V.
    Fenaux, P.
    Mufti, G. J.
    Hellstroem-Lindberg, E.
    List, A. F.
    Silverman, L. R.
    Seymour, J. F.
    Backstrom, J.
    McKenzie, D.
    Beach, C. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [23] THERAPY-RELATED MYELODYSPLASTIC SYNDROME: AN ANALYSIS OF 5 RISK MODELS IN PATIENTS TREATED WITH AZACITIDINE
    Duong, V.
    Lancet, J.
    Al-Ali, N.
    List, A.
    Komrokji, R.
    HAEMATOLOGICA, 2012, 97 : 368 - 369
  • [24] Clinical Significance of Additional Cytogenetic Abnormalities (ACA) at Disease Progression in Patients with High-Risk Myelodysplastic Syndrome (MDS) Treated with Azacitidine
    Naito, Chiaki
    Shimizu, Hiroaki
    Miyazawa, Yuri
    Ishizaki, Takuma
    Yokohama, Akihiko
    Saito, Takayuki
    Tsukamoto, Norifumi
    Handa, Hiroshi
    BLOOD, 2019, 134
  • [25] Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure
    Prebet, Thomas
    Gore, Steven D.
    Esterni, Benjamin
    Gardin, Claude
    Itzykson, Raphael
    Thepot, Sylvain
    Dreyfus, Francois
    Rauzy, Odile Beyne
    Recher, Christian
    Ades, Lionel
    Quesnel, Bruno
    Beach, C. L.
    Fenaux, Pierre
    Vey, Norbert
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (24) : 3322 - 3327
  • [26] Myelodysplastic Syndrome Azacitidine - useful therapeutic option in high-risk MDS
    Arnheim, Katharina
    ONKOLOGIE, 2010, 33 (12): : 720 - 721
  • [27] INVASIVE FUNGAL INFECTIONS IN PATIENTS WITH HIGH-RISK MDS AND AML TREATED WITH AZACITIDINE
    Pomares Marin, H.
    Arnan Sangerman, M.
    Sanchez-Ortega Sanchez, I.
    Duarte Palomino, R. D.
    LEUKEMIA RESEARCH, 2015, 39 : S145 - S146
  • [28] Invasive Fungal Infections in Patients with High-Risk MDS and AML Treated with Azacitidine
    Pomares, Helena
    Arnan, Montserrat
    Sanchez-Ortega, Isabel
    Sureda, Anna
    Duarte, Rafael F.
    BLOOD, 2015, 126 (23)
  • [29] Cytogenetic response is not a prerequisite for clinical response in patients with myelodysplastic syndromes treated with azacitidine
    Gangatharan, Shane A.
    Carney, Dennis A.
    Campbell, Lynda J.
    Prince, H. Miles
    Kenealy, Melita K.
    Seymour, John F.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2011, 87 (02) : 186 - 188
  • [30] Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine
    Sebert, Marie
    Komrokji, Rami S.
    Sekeres, Mikkael A.
    Prebet, Thomas
    Cluzeau, Thomas
    Santini, Valeria
    Gyan, Emmanuel
    Sanna, Alessandro
    Ali, Najla Hai
    Hobson, Sean
    Eclache, Virginie
    List, Alan
    Fenaux, Pierre
    Ades, Lionel
    LEUKEMIA RESEARCH, 2017, 63 : 72 - 77
12345